In lung cancer, SMARCA4 gene mutations account for 12% of non-oncogenic addictive lung adenocarcinomas, with 5% of these mutations also present in oncogenic lung adenocarcinomas (1). This evidence concerns the gene SMARCA4 and lung cancer.